Phase IIb Study of STA-2 in Patients With Chronic Stable Angina

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by Sinphar Pharmaceutical Co., Ltd.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Sinphar Pharmaceutical Co., Ltd
ClinicalTrials.gov Identifier:
NCT01239511
First received: November 10, 2010
Last updated: August 10, 2011
Last verified: August 2011
  Purpose

The objective of this study is to evaluate the dose-response of three different dose levels of STA-2 (900 mg daily, 1800 mg daily and 2700 mg daily for 42 days) versus placebo in patients with chronic stable angina.


Condition Intervention Phase
Chronic Stable Angina
Drug: green tea polyphenols (STA-2)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Dose-Response and Safety of STA-2 in Patients With Chronic Stable Angina

Resource links provided by NLM:


Further study details as provided by Sinphar Pharmaceutical Co., Ltd:

Primary Outcome Measures:
  • Change in total exercise time [ Time Frame: 6 weeks after the first exercise tolerance testing is conducted ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in time to onset of angina from baseline to the final visit [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Changes in time to 1mm ST-segment depression during ETT from baseline to final visit [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Changes in time to maximum ST-segment depression during ETT from baseline to the final visit [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: December 2010
Estimated Study Completion Date: May 2012
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo group Drug: green tea polyphenols (STA-2)
2 capsules t.i.d., after meal
Experimental: Treatment Group A
150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)
Drug: green tea polyphenols (STA-2)
2 capsules t.i.d., after meal
Experimental: Treatment Group B
300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)
Drug: green tea polyphenols (STA-2)
2 capsules t.i.d., after meal
Experimental: Treatment Group C
450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)
Drug: green tea polyphenols (STA-2)
2 capsules t.i.d., after meal

Detailed Description:

The objective of this study is to evaluate the dose-response of three different dose levels of STA-2 (900 mg daily, 1800 mg daily and 2700 mg daily for 42 days) versus placebo in patients with chronic stable angina.

Treatment Group A:

150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)

Treatment Group B:

300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)

Treatment Group C:

450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)

Placebo Group:

Placebo capsule, 2 capsules t.i.d., after meal

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female aged ≧ 20 years;
  2. Patients who had more than 50% coronary stenosis documented by catheterization or ever received coronary intervention;
  3. The two ETT results at screening (Visit 1) and baseline (Visit 2) show greater than or equal to 1 mm ST-segment depression within exercise duration;
  4. The difference in exercise duration between screening (Visit 1) and baseline (Visit 2) do not exceed 20% of the longer test;
  5. Able to provide written informed consent.

Exclusion Criteria:

  • 1) Patients with pacemaker rhythm, unstable angina or myocardial infarction within the preceding 3 months; 2) Patients with heart failure (New York Heart Association class III or IV), uncorrected valvular or congenital heart disease, patients who need digoxin or digitalis; 3) Patients with any resting EKG abnormalities preventing the interpretation of ischemia as judged by the investigator; 4) Patients with COPD requiring bronchodilators; 5) Patients with impaired hepatic function (defined as AST and/or ALT > 3X the upper limit of normal values), and/or impaired renal function (defined as serum creatinine > 2 mg/dL); 6) Patients with documented evidence of gastroduodenal ulcer disease, gastrointestinal bleeding or other gastrointestinal disease within the preceding 3 months as judged by investigator; 7) Patients who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event or interfere with safety assessments during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, immune, neurological, or hematological disease as determined by the clinical judgment of the investigator; 8) Patient with any conditions that could interfere the performance of exercise tolerance test as judged by investigator (e.g., knee/ankle arthropathy, Parkinsonism, stoke); 9) Female patients of childbearing potential who:
  • are lactating;
  • have positive pregnancy test (urine) at V1; 10) Patient has received any investigational agent within 28 days prior to the first dose of investigational product; 11) Patients who have had administered STA-2 in prior clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01239511

Contacts
Contact: Douglas Chen swchen1@sinphar.com.tw

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Chuen-Den Tseng, Taiwan
Contact: Chuen-Den Tseng       cdtseng@ha.mc.ntu.edu.tw   
Chi Mei Medical Center Not yet recruiting
Tainan, Taiwan
Contact: Tsung-Ming Lee         
Principal Investigator: Tsung-Ming Lee         
Sponsors and Collaborators
Sinphar Pharmaceutical Co., Ltd
Investigators
Principal Investigator: Chuen-Den Tseng, MD, Ph.D Department of Cardiology National Taiwan University Hospital
  More Information

No publications provided

Responsible Party: Justine Tang/Manager, Sinphar Pharmaceutical Co., Ltd
ClinicalTrials.gov Identifier: NCT01239511     History of Changes
Other Study ID Numbers: MCCD09004A
Study First Received: November 10, 2010
Last Updated: August 10, 2011
Health Authority: Taiwan: Department of Health
United States: Food and Drug Administration

Additional relevant MeSH terms:
Angina Pectoris
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Chest Pain
Pain
Signs and Symptoms

ClinicalTrials.gov processed this record on July 26, 2014